To address this, targeted therapies such as fisogatinib (BLU-554) have been developed, specifically inhibiting the FGF19/FGFR4 pathway and showing potential in curbing HCC progression 12. The gene discussed is FGFR4; the disease is hepatocellular carcinoma.